Table 2.
Survival Analysis of Self-Reported Symptoms in HTLV-1–Infected Subjects Without Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)–Associated Myelopathy/Tropical Spastic Paraparesis
| Symptom | Initial Population Without Respective Symptom, no./No. (%) | Sample With Follow-up, no./No. (%) Follow-up Data Available | Proportion of Failures, no./No. (%) | Median Person-time Observation, y (Max-Min) | Incidence Rate/1000 Person-years (95% Confidence Interval) |
|---|---|---|---|---|---|
| Sensory symptoms | |||||
| Hand numbness | 173/251 (68.9) | 129/173 (74.5) | 73/129 (56.6) | 2 (1–7) | 206.2 (163–259) |
| Foot numbness | 188/251 (73.7) | 141/188 (75.0) | 76/141 (53.9) | 2 (1–7) | 186.7 (149–233) |
| Urinary symptoms | |||||
| Nocturia | 214/251 (85.2) | 160/214 (74.7) | 65/160 (40.6) | 2 (1–7) | 129.7 (101–165) |
| Urgency | 251/251 (100) | 187/251 (74.5) | 73/187 (19.0) | 2 (1–7) | 126.9 (100–159) |
| Retention | 238/251 (94.8) | 178/238 (74.7) | 50/178 (28.0) | 3 (1–7) | 79.1 (59–104) |
| Incontinence | 226/251 (90.0) | 169/226 (74.7) | 69/169 (40.8) | 5 (1–7) | 95.8 (75–121) |
| Motor symptoms | |||||
| Difficulty walking | 221/251 (88.0) | 164/221 (74.2) | 64/164 (39.0) | 2 (1–7) | 124.0 (97–158) |
| Difficulty running | 215/251 (85.6) | 159/215 (73.9) | 77/159 (48.4) | 2 (1–7) | 177.4 (141–221) |